Patents Represented by Attorney, Agent or Law Firm Janet Sleath
  • Patent number: 5710174
    Abstract: A compound that is useful for inhibiting FXIIIa catalysis of fibrin cross-linking, and related pharmaceutical compositions and methods, are disclosed. The compound and compositions may be advantageously used to enhance fibrinolysis and resolution of blood clots.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 20, 1998
    Assignees: Zymo Genetics, Inc., Novo Nordisk A/S
    Inventors: Robert R. West, Teresa Martinez, Hank R. Franklin, Paul D. Bishop, Birgitte R.o slashed.mer Rassing
  • Patent number: 5699798
    Abstract: The present invention provides a method and apparatus for determining the presence of solid tumor tissue, for identifying and mapping the margins of solid tumors during surgical or diagnostic procedures, and for grading and characterizing tumor tissue by detecting changes in the optical properties of an area of interest suspected to contain tumor tissue.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 23, 1997
    Assignee: University of Washington
    Inventors: Daryl Hochman, Michael M. Haglund
  • Patent number: 5677146
    Abstract: The present invention provides isolated DNA molecules comprising a DNA segment encoding a novel human amyloid protein precursor homologue and novel Kunitz-type inhibitors. Also provided are DNA constructs comprising a first DNA segment encoding a novel human amyloid protein precursor homologue or a novel Kunitz-type inhibitor wherein said first DNA segment is operably linked to additional DNA segments required for the expression for the first DNA segment, as well as host cells containing such DNA constructs and methods for producing proteins from the host cells.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: October 14, 1997
    Assignee: Zymogenetics, Inc.
    Inventors: Cindy A. Sprecher, Donald C. Foster, Kjeld E. Norris
  • Patent number: 5629286
    Abstract: The present invention comprises homeopathic dilutions of growth factors and methods for their use. Disorders which may be effectively treated with the compositions of the present invention include chronic viral disorders, such as HIV, AIDS, chronic fatigue syndrome and Epstein-Barr viral infections, cancer and diabetes. Homeopathic dilutions of growth factors are preferably administered orally. In an alternative embodiment, patients are treated with radio frequency signals corresponding to homeopathic dilutions of growth factors.
    Type: Grant
    Filed: September 10, 1996
    Date of Patent: May 13, 1997
    Inventor: Barbara Brewitt
  • Patent number: 5626617
    Abstract: The present invention comprises homeopathic dilutions of growth factors and methods for their use. Disorders which may be effectively treated with the compositions of the present invention include chronic viral disorders, such as HIV, AIDS, chronic fatigue syndrome and Epstein-Barr viral infections, cancer and diabetes. Homeopathic dilutions of growth factors are preferably administered orally. In an alternative embodiment, patients are treated with electromagnetic signals, preferably radiofrequency signals, corresponding to homeopathic dilutions of growth factors.
    Type: Grant
    Filed: December 20, 1995
    Date of Patent: May 6, 1997
    Inventor: Barbara Brewitt
  • Patent number: 5525526
    Abstract: Antibodies raised against derivatives of inositol are used to assay for specific isomers of inositol in a sample by first converting any inositol present in the sample to the derivative that was used to raise the antibody and then conducting an immunoassay for the inositol derivative in a conventional manner.
    Type: Grant
    Filed: February 2, 1994
    Date of Patent: June 11, 1996
    Assignee: The University of Virginia Patent Foundation
    Inventors: Joel Linden, Thomas Piccariello, George Vandenhoff
  • Patent number: 5427956
    Abstract: An enhanced quantitative assay for chiro-inositol concentration can be used to determine insulin-resistance, or a predisposition to the development of insulin-resistance, in type I and type II diabetics. Spot urine or serum samples reflecting concentrations of chiro-inositol below about 1.0 micrograms/ml in urine or 0.1 micrograms/ml in serum are indicative of a predisposition to the development of insulin-resistance, while concentrations below about 0.3 micrograms/ml or 0.03 micrograms/ml in serum are associated with actual insulin-resistance symptoms. The assay can be employed for patient diagnosis, insulin therapy monitoring, and family screening.
    Type: Grant
    Filed: September 30, 1992
    Date of Patent: June 27, 1995
    Assignee: The University of Virginia Patent Foundation
    Inventors: Alison S. Kennington, Joseph Larner
  • Patent number: 5428066
    Abstract: A method of treating a cluster of diseases associated with elevated blood sugar levels comprising the administration of a dietary supplement of chiro-inositol. Chiro-inositol is an essential element for the synthesis of an insulin-directed mediator apparently responsible for the activation of pyruvate dehydrogenase-phosphatase. Disease conditions commonly associated with insulin-resistance, such as hypertension, lactic acidosis, obesity, coronary artery disease, and the like, are treated by administration of sufficient chiro-inositol to meet normal metabolic levels.
    Type: Grant
    Filed: September 12, 1994
    Date of Patent: June 27, 1995
    Inventors: Joseph Larner, Alison Kennington, Laura C. Huang
  • Patent number: 5406005
    Abstract: The invention relates to the synthesis of D-chiro-inositol from glucodialdose comprising the steps of condensing glucodialdose by a acylon condensation reaction, protecting the carbon atoms of the 1,2,5 and 6 position, epimerizing the protected carbon atom at position 5, reducing the ketone of the condensed compound and removing the protect groups.
    Type: Grant
    Filed: April 15, 1994
    Date of Patent: April 11, 1995
    Inventor: Thomas Piccariello
  • Patent number: 5322084
    Abstract: The present invention is a foot operated control device that provides variable control by means of a single foot pedal. The foot operated control device can be locked to allow continuous unattended operation. The foot pedal can be flipped into an upper position, for example into a cabinet. In a preferred embodiment of the invention, the foot operated control device comprises a foot operated faucet.
    Type: Grant
    Filed: August 30, 1993
    Date of Patent: June 21, 1994
    Assignee: Hilltop Corporation
    Inventor: Hassan Ghiassian